AI Drug Discovery: GPU Planning for Protein and Molecular Models
Overview
Computational drug discovery has become GPU-dependent across its whole pipeline, but the demand is not uniform. Structure prediction is bursty and memory-hungry; virtual screening is embarrassingly parallel and throughput-bound; molecular dynamics is long-running and latency-insensitive but extremely sensitive to interconnect if distributed. Indian pharmaceutical and biotech teams frequently size a cluster for one of these and find it unsuitable for the others. This article separates the workloads and gives a planning method for each.
Key takeaways
- Four distinct workloads — structure prediction, generative design, docking and dynamics, each with a different profile.
- Structure prediction is memory-bound and bursty; large complexes need high-VRAM accelerators.
- Virtual screening is the throughput case — millions of independent evaluations, ideal for many GPUs.
- Molecular dynamics is long-running and, distributed, becomes interconnect-sensitive.
- Chemistry data is IP, not personal data — the governance driver is confidentiality, not DPDP.
Structure prediction
Predicting the three-dimensional structure of a protein or complex from sequence is now routine, and it is the stage that changed discovery workflows most. The compute profile is distinctive: individual predictions run in minutes to hours, memory requirement scales sharply with sequence length and complex size, and demand is bursty — a project generates a batch of predictions, then goes quiet while chemists work on the results.
The practical sizing implication is high-VRAM accelerators rather than many small ones, since a large multi-chain complex may not fit at all on a modest card, and a queue rather than dedicated per-scientist hardware, since the burstiness wastes dedicated capacity. Multiple sequence alignment generation, a CPU and I/O heavy preprocessing step, is frequently the actual bottleneck and deserves its own capacity planning.
Generative chemistry and virtual screening
Generative models propose candidate molecules; screening evaluates enormous libraries against a target. Both are throughput problems with no latency requirement, and both parallelise almost perfectly — each molecule is independent. This is the easiest workload to scale and the best candidate for rented or shared capacity, because it runs as a batch campaign rather than continuously.
Two planning notes. Screening scale has grown faster than hardware: libraries of billions of compounds are now tractable, and the constraint becomes whether you can store and stream the library rather than whether you can evaluate it. And the scoring function matters more than the throughput — screening a billion compounds with a poor scoring function produces a billion poor answers faster, so investment in better scoring beats investment in more GPUs.
Molecular dynamics
| Workload | Duration | Parallelism | Key hardware factor |
|---|---|---|---|
| Structure prediction | Minutes to hours | Across jobs | VRAM capacity |
| Generative design | Hours, batch | Near perfect | GPU count |
| Virtual screening | Hours to days, batch | Near perfect | GPU count and library I/O |
| Molecular dynamics, single | Days to weeks | Limited within a job | Single-GPU speed |
| Molecular dynamics, distributed | Days | Strong scaling limited | Interconnect latency |
| Free energy calculations | Days, many replicas | Across replicas | GPU count |
Molecular dynamics deserves attention because it scales differently from everything else. A single long simulation has limited internal parallelism, so more GPUs do not straightforwardly make it faster; beyond a point, communication overhead dominates and adding hardware slows it down. The productive pattern is many independent replicas rather than one heavily distributed run, which converts a strong-scaling problem into a throughput problem.
Sizing a discovery cluster
Work from the project portfolio rather than from any single workload. A typical mid-size Indian discovery group runs several projects concurrently, each cycling through prediction, design, screening and simulation at different times. That produces a mixed, spiky demand that suits a shared cluster with a scheduler far better than dedicated per-team hardware.
Three specifications matter. High-VRAM nodes for structure prediction and large-system dynamics, sized by the largest system you expect to study. A larger pool of standard nodes for screening and replica simulations, where GPU count is what matters. And genuine attention to storage: trajectory files from molecular dynamics are enormous, compound libraries are large, and a discovery group can accumulate hundreds of terabytes within a couple of years. Retention policy is essential, particularly at current flash pricing described in the 2026 memory and NAND squeeze.
Governance is about IP, not patients
Drug discovery data is unusual among healthcare workloads in that it rarely contains personal data. Compound structures, assay results and simulation trajectories are commercial intellectual property, sometimes the most valuable assets a company holds, but they are not patient records. The governance driver is therefore confidentiality and trade secret protection rather than DPDP.
That changes the placement calculus. There is no residency mandate, so rented capacity is legally straightforward, but there is a strong commercial reason to keep pre-competitive structures and hit series inside the company boundary — and collaboration agreements with partners frequently impose contractual restrictions on where data may be processed. The exception is any programme touching clinical trial data or patient samples, which reverts fully to the personal-data regime covered in healthcare AI infrastructure readiness.
Where Indian teams should start
Structure prediction offers the fastest return, because it removes a step that previously required crystallography or homology modelling and because the tooling is mature and open. A modest high-VRAM capability plus good MSA preprocessing serves most groups’ prediction needs and is a defensible first purchase.
Screening capacity is the natural second investment, and it is the best candidate for burst capacity rather than owned hardware given its campaign-shaped demand — India’s subsidised national compute at rates near a dollar per GPU-hour fits this profile well. Molecular dynamics is the most infrastructure-intensive and should follow demonstrated need rather than lead the build. The genomics-side sizing, which shares the batch-throughput character, is covered in GPU-accelerated genomics.
Frequently asked questions
Which drug discovery workloads need GPUs most?
All four main stages benefit, but differently. Structure prediction is memory-bound and bursty, generative design and virtual screening are throughput problems that parallelise almost perfectly, and molecular dynamics is long-running with limited internal parallelism.
Why does molecular dynamics scale poorly across GPUs?
A single simulation has limited internal parallelism, so communication overhead dominates beyond a modest GPU count and adding hardware can slow it down. Running many independent replicas instead converts it into a throughput problem that scales cleanly.
What is the bottleneck in structure prediction?
Frequently the multiple sequence alignment preprocessing, which is CPU and I/O heavy rather than GPU-bound, and VRAM capacity for large multi-chain complexes. Both are commonly overlooked when teams size purely on GPU throughput.
Does drug discovery data fall under DPDP?
Usually not. Compound structures, assay results and trajectories are commercial intellectual property rather than personal data. The governance driver is confidentiality and partner contract terms. Programmes touching clinical trial data or patient samples revert to the personal-data regime.
What should an Indian discovery group buy first?
A modest high-VRAM capability for structure prediction with good preprocessing capacity, since that delivers the fastest return on mature tooling. Screening suits burst or rented capacity given its campaign-shaped demand, and molecular dynamics should follow demonstrated need.
Ready to deploy?
Talk to an RDP architect about power, cooling and lead time.